Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meredith M Regan

Showing results (101-110 of 260) with videos related to

Pageof 26
Sort By:
Breast Cancer Research and Treatment|March 13, 2009
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapyEugenio Maiorano, Meredith M Regan, Giuseppe Viale, et al.
Future Oncology (London, England)|October 11, 2013
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancerErica Moretti, Christine Desmedt, Chiara Biagioni, et al.
Cancer|February 23, 2008
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effectRobert W Ross, Wanling Xie, Meredith M Regan, et al.
Cancer|April 2, 2019
Prevalence of germline variants in inflammatory breast cancerHuma Q Rana, Rosalba Sacca, Christine Drogan, et al.
Annals of Surgical Oncology|March 21, 2015
Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional ManagementLaura E G Warren, Hao Guo, Meredith M Regan, et al.
Breast Cancer Research and Treatment|April 21, 2015
Inflammatory breast cancer and development of brain metastases: risk factors and outcomesLaura E G Warren, Hao Guo, Meredith M Regan, et al.
BJU International|March 17, 2010
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapyToni K Choueiri, Meredith M Regan, Jonathan E Rosenberg, et al.
Urology|February 20, 2004
Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancerDaniel J George, Meredith M Regan, William K Oh, et al.
Journal of the National Cancer Institute|August 21, 2013
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNAJames M Rae, Meredith M Regan, Jacklyn N Thibert, et al.
The Breast Journal|August 27, 2019
Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experienceFaina Nakhlis, Meredith M Regan, Yoon S Chun, et al.
Pageof 26

Showing results (101-110 of 260) with videos related to

Sort By:
Pageof 26
Breast Cancer Research and Treatment|March 13, 2009
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapyEugenio Maiorano, Meredith M Regan, Giuseppe Viale, et al.
Future Oncology (London, England)|October 11, 2013
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancerErica Moretti, Christine Desmedt, Chiara Biagioni, et al.
Cancer|February 23, 2008
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effectRobert W Ross, Wanling Xie, Meredith M Regan, et al.
Cancer|April 2, 2019
Prevalence of germline variants in inflammatory breast cancerHuma Q Rana, Rosalba Sacca, Christine Drogan, et al.
Annals of Surgical Oncology|March 21, 2015
Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional ManagementLaura E G Warren, Hao Guo, Meredith M Regan, et al.
Breast Cancer Research and Treatment|April 21, 2015
Inflammatory breast cancer and development of brain metastases: risk factors and outcomesLaura E G Warren, Hao Guo, Meredith M Regan, et al.
BJU International|March 17, 2010
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapyToni K Choueiri, Meredith M Regan, Jonathan E Rosenberg, et al.
Urology|February 20, 2004
Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancerDaniel J George, Meredith M Regan, William K Oh, et al.
Journal of the National Cancer Institute|August 21, 2013
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNAJames M Rae, Meredith M Regan, Jacklyn N Thibert, et al.
The Breast Journal|August 27, 2019
Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experienceFaina Nakhlis, Meredith M Regan, Yoon S Chun, et al.
Pageof 26